OncRef

Clinical Trial: NCT06551324

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Pfizer
Information Provided By:Pfizer
Last Update Posted:2026-08-11

Study Overview

Brief Summary

Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.

The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.

Official Title

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Intervention / Treatment

  • Drug: PF-06821497
  • Drug: Docetaxel
  • Drug: Enzalutamide

Other Study ID Numbers

  • C2321014
  • 2024-511650-50-00

Start Date (Actual)

2024-10-21

Primary Completion Date (Estimated)

2026-12-28

Study Completion Date (Estimated)

2028-10-29

Enrollment (Estimated)

600

Study Type

Interventional

Phase

Phase 3